News

Life Sciences

​Biotech in 2019: Gene Therapies, Cancer Immunotherapies, and mRNA

Guild Investment Management | Equities.com |

Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well).


PetVivo: Microcap Play in $18 Billion Veterinary Care Market

Edward Kim | Equities.com |

Lead product for osteoarthritis in dogs and lameness from navicular disease in horses (Image: PetVivo).


Generex Acquires Majority Stake in Olaregen Therapeutix to Enter Wound Healing Market

Edward Kim | Equities.com |

Olaregen's Excellagen (flowable dermal matrix) is FDA approved for wound management in multiple indications (Image: Olaregen Therapeutix)


X4 Pharmaceuticals to Become Public via Reverse Merger with Arsanis

Edward Kim | Equities.com |

Phase 3 trial for X4's lead candidate anticipated to start in the first half of 2019 in WHIM syndrome (Image: X4 Pharmaceuticals).


Applied DNA's SigNature Anti-Theft Molecular Tags Lead to Successful Criminal Convictions

Edward Kim | Equities.com |

Over 131 convictions, with sentences of 625 years to date and more cases in the pipeline (Image: Applied DNA Sciences).


Loxo Oncology Awaiting FDA's Decision Monday on Lead Cancer Therapeutic

Edward Kim | Equities.com |

Monday, Nov. 26th, is the PDUFA date for larotrectinib, Loxo's candidate to treat TRK fusion cancers (Image: Loxo Oncology)


Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

Edward Kim | Equities.com |

First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)


GlycoMimetics Doses First Patient in Phase 3 Advanced Acute Myeloid Leukemia Study

Edward Kim | Equities.com |

Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)


Cadent Therapeutics Raises $40 Million Series B for Movement and Cognitive Disorders

Edward Kim | Equities.com |

Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).


Attenua Treats First Patient in Phase 2 Study for Chronic Cough

Edward Kim | Equities.com |

Phase 2 trial for non-opioid chronic cough therapy initiated just 6 months after Series A funding (Image: Attenua)


Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more